| 344 | 11 | 110 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 分析子宫内膜不典型增生/早期子宫内膜癌(AH/EEC)患者保留生育功能治疗后接受体外受精-胚胎移植(IVF-ET)治疗的临床特点和预后，分析影响助孕妊娠结局和疾病复发的主要因素。方法 回顾性分析2012年2月至2022年2月在北京协和医院接受AH/EEC生育保留治疗后进行IVF-ET治疗的78例患者的临床资料。总结分析纳入患者的临床特征、IVF-ET相关指标、妊娠结局和复发情况，以单因素和多因素分析临床妊娠率、活产率以及疾病复发的影响因素。结果 78例患者中51例(65.38%)为AH患者，27例(34.62%)为EEC患者；开始IVF-ET周期的平均年龄为(34.17±3.70)岁。共有74例患者至少接受了1次移植，每移植周期的临床妊娠率和活产率分别为36.31%(65/179)和18.99%(34/179),累积妊娠率为72.97%(54/74)。多因素分析提示子宫内膜病变初次发病年龄是活产率的独立影响因素[OR=0.879 4,95%CI(0.785,0.983),P=0.02]。纳入患者IVF-ET期间子宫内膜病变的总复发率为6.41%(5/78),多因素分析提示子宫内膜病变的病理类型和IVF-ET前复发史是疾病复发的危险因素(P<0.05)。结论 AH/EEC患者保留生育功能治疗后的辅助生殖结局相对满意，在肿瘤治疗过程中，进行病变评估时应尽量保护内膜，减少损伤；在肿瘤治疗结束后，应尽快进行助孕治疗，以最大程度降低复发率。
Abstract：Objective:To summarize the clinical characteristics and prognosis of patients undergoing in vitro fertilization-embryo transfer(IVF-ET) after fertility-sparing treatment for atypical endometrial hyperplasia and early endometrial cancer(AH/EEC),and to analyze the main factors for reproductive outcomes and disease recurrence.Methods:A retrospective analysis was performed for the clinical data of patients who received assisted reproductive technology(ART) treatment after AH/EEC fertility-sparing treatment in Peking Union Medical College Hospital from February 2012 to February 2022. Clinical features, indicators related to IVF-ET,reproductive outcomes and recurrence were summarized. Risk factors for clinical pregnancy and live birth rates as well as recurrence rates were evaluated with univariate and multivariate analyses.Results:A total of 78 patients recruited in the study. There are 51(65.38%) AH patients and 27(34.62%) EEC ones. The average age at the initiation of an IVF-ET cycle was 34.17±3.70 years. A total of 74 patients received at least one time of embryo transfer. The clinical pregnancy rate and live birth rate per ET were 36.31%(65/179) and 18.99%(34/179),respectively, and the cumulative pregnancy rate was 72.97%(54/74). Multivariate analysis suggests that the initial onset age of AH/EEC was the independent risk factor for live birth rate [OR=0.879 4,95%CI(0.785,0.983),P=0.02]. The overall recurrence rate of AH/EEC in IVF-ET cycle was 6.41%(5/78). Both the pathological type of endometrial lesions and the history of recurrence before IVF-ET were significantly correlated with the recurrence of disease(P<0.05).Conclusions:The reproduction outcomes after fertility-sparing treatment are relatively satisfied. Attention should be paid to protecting the endometrium and reducing damage during evaluation of the endometrial lesion. Fertility treatment should be given as soon as possible after the oncology treatment to minimize the recurrence rate.
[1] National Cancer Institute.Surveillance epidemiology and end results.Available at:http://seer.cancer.gov/statistics/.Accessed May 15,2012.
[2] 高劲松，沈铿，郎景和，等.45岁以下子宫内膜癌患者的临床分析[J].中华妇产科杂志，2004,39:159-161.
[3] Yu M,Yang JX,Wu M,et al.Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium[J].Fertil Steril,2009,92:2122-2124.
[4] Bj?rge T,Stocks T,Lukanova A,et al.Metabolic syndrome and endometrial carcinoma[J].Am J Epidemiol,2010,171:892-902.
[5] Duska LR,Garrett A,Rueda BR,et al.Endometrial cancer in women 40 years old or younger[J].Gynecol Oncol,2001,83:388-393.
[6] Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,2:87-108.
[7] Gotlieb WH,Beiner ME,Shalmon B,et al.Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer[J].Obstet Gynecol,2003,102:718-725.
[8] Gadducci A,Spirito N,Baroni B,et al.The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer:a debated therapeutic option[J].Gynecol Endocrinol,2009,25:683-691.
[9] Baek JS,Lee WH,Kang WD,et al.Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin:is it effective?[J].Obstet Gynecol Sci,2016,59:24-31.
[10] Pronin SM,Novikova OV,Andreeva JY,et al.Fertility sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential[J].Int J Gynecol Cancer,2015,25:1010-1014.
[11] Gallos ID,Yap J,Rajkhowa M,et al.Regression,relapse,and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia:a systematic review and meta-analysis[J].Am J Obstet Gynecol,2012,207:266.
[12] Fujimoto A,Ichinose M,Harada M,et al.The outcome of infertility treatment in patients undergoing assisted reproductive technology after conservative therapy for endometrial cancer[J].J Assist Reprod Genet,2014,31:1189-1194.
[13] Li M,Song JL,Zhao Y,et al.Fertility outcomes in infertile women with complex hyperplasia or complex atypical hyperplasia who received progestin therapy and in vitro fertilization[J].J Zhejiang Univ Sci B,2017,18:1022-1025.
[14] Inoue O,Hamatani T,Susumu N,et al.Factors affecting pregnancy outcomes in young women treated with fertility preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia[J].Reprod Biol Endocrinol,2016,14:2.
[15] 肖亚玲，孙正怡，王雪，等.早期子宫内膜癌和子宫内膜非典型增生患者保守治疗后的IVF-ET治疗结局[J].生殖医学杂志，2021,30:1-6.
[16] Wang Y,Yu M,Yang JX,et al.Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy:15-year experience[J].Int J Clin Onco,2019,24:712-720.
[17] Zhou H,Cao DY,Yang JX,et al Gonadotropin-releasing hormone agonist combined with a levonorgestrel-releasing intrauterine system or letrozole for fertility-preserving treatment of endometrial carcinoma and complex atypical hyperplasia in young women[J].Int J Gynecol Cancer,2017,27:1178-1182.
[18] 康卫卫，黄剑磊，孙丹，等.子宫内膜增生不伴不典型增生不孕症药物治疗结束至胚胎移植间隔与临床妊娠率的关系[J].生殖医学杂志，2021,30:620-625.
基本信息:
中图分类号:R714.8
引用信息:
[1]陶陶,邓成艳,王含必,等.子宫内膜不典型增生/早期子宫内膜癌患者保留生育功能治疗后IVF-ET妊娠结局及复发因素分析[J].生殖医学杂志,2024,33(03):283-290.
基金信息:
北京协和医院中央高水平临床科研专项(2022-PUMCH-B-080)
2024-03-15
2024-03-15